Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , Massachusetts 02115 , United States.
CeMM Research Center for Molecular Medicine of the Austrian Academy of Science , Lazarettgasse 14, AKH Bt. 25.3 , 1090 Vienna , Austria.
ACS Chem Biol. 2018 Mar 16;13(3):553-560. doi: 10.1021/acschembio.7b00969. Epub 2018 Jan 29.
Protein degradation is an emerging therapeutic strategy with a unique molecular pharmacology that enables the disruption of all functions associated with a target. This is particularly relevant for proteins depending on molecular scaffolding, such as transcription factors or receptor tyrosine kinases (RTKs). To address tractability of multiple RTKs for chemical degradation by the E3 ligase CUL4-RBX1-DDB1-CRBN (CRL4), we synthesized a series of phthalimide degraders based on the promiscuous kinase inhibitors sunitinib and PHA665752. While both series failed to induce degradation of their consensus targets, individual molecules displayed pronounced efficacy in leukemia cell lines. Orthogonal target identification supported by molecular docking led us to identify the translation termination factor G1 to S phase transition 1 (GSPT1) as a converging off-target, resulting from inadvertent E3 ligase modulation. This research highlights the importance of monitoring degradation events that are independent of the respective targeting ligand as a unique feature of small-molecule degraders.
蛋白质降解是一种新兴的治疗策略,具有独特的分子药理学,能够破坏与靶标相关的所有功能。对于依赖分子支架的蛋白质,如转录因子或受体酪氨酸激酶 (RTKs),这一点尤为重要。为了解决 E3 连接酶 CUL4-RBX1-DDB1-CRBN (CRL4) 对多种 RTKs 进行化学降解的可处理性,我们合成了一系列基于泛激酶抑制剂舒尼替尼和 PHA665752 的邻苯二甲酰亚胺降解剂。虽然这两个系列都未能诱导其共识靶标的降解,但个别分子在白血病细胞系中表现出明显的疗效。通过分子对接支持的正交靶标鉴定,我们将翻译终止因子 G1 到 S 期转变 1 (GSPT1) 鉴定为一个趋同的脱靶,这是由于无意中调节了 E3 连接酶。这项研究强调了监测与各自靶向配体无关的降解事件的重要性,这是小分子降解剂的一个独特特征。